Eikon Therapeutics, Inc.

EIKN Nasdaq CIK: 0001861123

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030
Mailing Address 230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030
Phone 341-777-0566
Fiscal Year End 1231
EIN 842807586

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 30, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 18, 2026 View on SEC

Annual Reports

10-K March 30, 2026
  • Led by CEO Roger Perlmutter, former head of R&D at Merck.
  • Proprietary 'Eikon Platform' utilizes super-resolution microscopy for drug discovery.
View Analysis

Insider Trading

STRONG BUY 5 insiders 9 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.